Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We expect gross margin to be approaching the mid-40s and slightly better than Q1 fiscal year 2024 |
| But by and large, that organization is also in place, and that's why we're seeing, we're starting to see really good traction |
| In Q2, we expect revenue growth to accelerate to mid- to high single digits |
| We have momentum that supports the guidance we announced at our November earnings call |
| In addition, new Products and Services offerings are gaining market momentum and we're winning larger contracts of bundled offerings for larger customers |
| Of note, our Multiomics business in China delivered another strong quarter with organic growth of 12% |
| And then free cash flow, yes, we feel good about where cash flow is coming in |
| And we further benefit from tailwinds generated by an industry trend to outsource more critical sample management and measurement |
| We see sustained long-term growth above the market rate that can persist for years to come |
| In addition, we've identified the potential for another strong growth factor that will utilize our core capabilities to allow us to add some of the rarest and most valuable biosamples into the discovery pipeline, samples that are sourced by us, managed by us, measured by us and owned by us |
| Our channel partners continue to see improvement and end-user demand is also showing signs of life with increased inquiries year-over-year |
| We're a great company and strong market-leading positions, serving a market in need of all that we do |
| Excluding B Medical, we saw operating margin expand 160 basis points |
| The interest income assumption here for 2Q is that just because of lower cash balance on share repurchase? And then the free cash flow performance in Q1 are pretty impressive |
| We continue to be extremely well positioned from a balance sheet perspective |
| And we had a lot of good opportunity there |
| Large Automated Stores revenue was up 37% year-over-year and Sample Repository Solutions was up a healthy 6% year-over-year, continuing the trends we saw in the September quarter |
| We feel good about where the pipeline is |
| We feel really comfortable about what that looks like and Herman defined the progress, it's a modest uptick from the first half to the second half, and we feel good about that |
| This new system designed to hold up to 10 million samples, offers unparalleled storage density |
| We have good line of sight, good visibility to the business on the Multiomics side on the SMS side |
| In C&I, we did see another 5% sequential improvement as we move from Q4 to Q1, and we believe that we have now cycled through the tough year-over-year compares |
| We hope before the year is over, that we can articulate what that program is specifically with numbers and units and samples in terms of what that's done from a transformative standpoint to add tremendous value to a product-based B medical vaccine cold chain to Services revenue for Azenta on the sample retrieval side |
| And that's why we're really enthusiastic about the DRC |
| Finally, we're also encouraged that Consumables & Instruments showed sequential growth for the second quarter in a row |
| So that we feel very confident about, and it's a similar situation as we talked about in on the Q4 call |
| In a very challenging market for Life Science Services, we're pleased that Multiomics delivered organic growth of 2% with yet another record revenue quarter in our next-generation sequencing business |
| So we believe China is fully capable, full speed ahead and just the growth characteristics they've exhibited so different from what's going on in the rest of the market, is attributed to a strong team aggressively going after all their local customer base |
| So we've seen strong growth in synthesis, really good recovery the issues we had in China 18 months ago are behind us, and we feel like we're in a really good position back to growth |
| I continue to be impressed by what I see and the opportunity that lies ahead |
| Statement |
|---|
| First quarter revenue was $154 million, down 13% year-over-year and down 15% on an organic basis |
| Gross margin of 28.1% was lower than last year, primarily driven by sales mix |
| Total revenue was $154 million, as anticipated, non-GAAP gross margin was down year-over-year, coming in at 43.5%, down 190 basis points |
| Revenue was $13 million in the quarter, down roughly 70% on a reported and organic basis |
| The Multiomics business gross margin was 47.1%, down 30 basis points year-over-year |
| Non-GAAP operating margin was negative 5.6%, down 560 basis points year-over-year |
| Adjusted EBITDA margin was 3%, down 370 basis points year-over-year, again, driven by the B Medical dynamics |
| As we have discussed in the past, the Consumables & Instruments business, or C&I, remained a headwind to growth in the quarter on a year-over-year basis |
| B Medical delivered $13 million of revenue, down 70% as expected |
| One, without question, this a little bit softer North America business has caused us some issues there, and we begin to transfer some of the Plasma EZ Sequencing into the NGS business |
| In Q1, we delivered revenue of $154 million, which translates to an organic decline of 15% year-over-year, but up 2% when you exclude the B Medical segment, which had a lighter Q1 due to the timing of orders as expected and up 5% when you also exclude our Consumables & Instruments business, which has faced the most notable headwind in the post-COVID time frame |
| As expected, the lower B Medical revenue drove the Q1 decline |
| I mean, you mentioned a lot of the things that help you maintain as best you can the margins there, but it sounds like certainly still some pricing pressures |
| We attributed to that because indeed, in North America, a lot of the Biotech funding has been off or down as companies have either reduced funding or gone out of business |
| It's when you get into biotech where you're still seeing a little bit of the funding pressure |
| The lower level of revenue was primarily due to timing of vaccine cold chain orders |
| You said you're confident in the contract, but then you mentioned kind of vehicle procurement and timing can be difficult |
| The lower level of revenue year-over-year is primarily due to the timing of orders |
| I will say for example, on the Sanger side that shrunk a little bit here in the last quarter |
| In general, pharma and academic funding remained steady to up modestly, but biotech continues to face funding constraints |
Please consider a small donation if you think this website provides you with relevant information